FEB 21, 2018 10:30 AM PST

Panel Discussion: Co-development of Drugs and Companion Diagnostics

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Associate-Professor, Pharmaceutical Sciences, Midwestern University
      An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she was with Cue Biotech and Caden Biosciences, companies she co-founded that focused on identifying modulators of G protein-coupled receptors (GPCRs) utilizing novel approaches (US Patent Numbers 6,559,128; 7,208,279; and 7,294,472). Her current research is on allosteric and functionally selective modulators of GPCRs with her primary receptors of interest being the chemokine receptor CCR1 and the recently deorphanized FFAR2. She is an International Editor for the British Journal of Clinical Pharmacology and recently served as a guest co-editor for a Frontiers in Endocrinology Bone Research themed issue on "Chemokines and Bone".
    • Business Development Manager at AroCell AB
        Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as qualified for use in toxicological testing. He developed strong relationships with hospitals, clinical research organizations and pharmaceutical companies, including AstraZeneca, Sanofi Aventis, Pfizer, Novartis, Merck, Glaxo Smith Kline and Johnson and Johnson.

        From 1975-1992 Martin Shaw filled many technical and marketing roles at Pharmacia Diagnostics (now Thermo-Fisher). He and his coworkers developed and introduced the first commercial tests for neonatal hypothyroidism, celiac disease, and a range of novel biomarkers to monitor allergy and inflammation.

        Bringing testing close to the patient is important and Martin brings this experience from being Marketing Manager at Magnasense Technologies, Finland, where he introduced and promoted a novel point-of-care test system based on magnetically labelled antibodies.

        Martin has published several peer-reviewed articles on biomarkers and presented at many scientific congresses, including being guest speaker at the FDA.
      • Professor and Department Chair, Chemical Engineering, Art Zafiropoulo Chair in Engineering, Affiliated Faculty, Bioengineering, Northeastern University, College of Engineering
          Thomas J. Webster's (H index: 80, Google Scholar) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995) and in biomedical engineering from Rensselaer Polytechnic Institute (M.S., 1997; Ph.D., 2000). Prof. Webster is the current director of the Nanomedicine Laboratories (currently at 23 members) and has completed extensive studies on the use of nanophase materials in medicine. He pioneered the use of nanomaterials to increase tissue growth, inhibit infection, and decrease inflammation. He was appointed Department Chair of Chemical Engineering at Northeastern University in 2012 in which the Department recently broke the record for the fastest increase in ranking over a five year period from the U.S. News and World Report. In his 17 years in academics, Prof. Webster has graduated/supervised over 149 visiting faculty, clinical fellows, post-doctoral students, and thesis completing B.S., M.S., and Ph.D. students. To date, his lab group has generated over 13 textbooks, 68 book chapters, 376 invited presentations, at least 503 peer-reviewed literature articles and/or conference proceedings, at least 767 conference presentations, and 42 provisional or full patents. His research has led to the formation of 12 companies with 4 FDA approved nanomedicine products. He is the founding editor-in-chief of the International Journal of Nanomedicine (the first open-access, international journal in nanomedicine which has a 5-year impact factor of 5.03). Prof. Webster currently directs or co-directs several centers in the area of biomaterials: The Center for Natural and Tropical Biomaterials (Medellin, Colombia), The Center for Pico and Nanomedicine (Wenzhou China), and The International Materials Research Center (Soochow, China). He was named the Art Zafiropoulo Chair at Northeastern University for his contributions to nanomedicine in 2013. Prof. Webster has received numerous honors including but not limited to: 2012, Fellow, American Institute for Medical and Biological Engineering (AIMBE, representing the top 2% of all medical and biological engineers); 2013, Fellow, Biomedical Engineering Society; 2015, Wenzhou 580 Award; 2015, Zheijang 1000 Talent Program; 2016, International Materials Research Chinese Academy of Science Lee-Hsun Lecture Award; 2016, International College of Fellows, Biomaterials Science and Engineering; and 2016, Acta Biomaterialia Silver Award. He also served as the President of the U.S. Society For Biomaterials. He has appeared on BBC, NBC, ABC, Fox News, the Weather Channel, the Discovery Channel, and the recent special 'Year Million' TV series on National Geographic talking about the future of medicine and science.


        The distinction between "complementary" and "companion" diagnostics tests confuse many physicians and healthcare professionals. Panelists Professor Thomas Webster (Northeastern University) and Dr. Martin Shaw (AroCell AB) will discuss the differences between "complementary" and "companion" diagnostics and why both are important. 

        Show Resources
        Loading Comments...